# Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Source: https://onco.cc/trials/nct06493552/  
OnCo record `nct06493552` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin in bladder & urothelial cancer, run by Vasgene Therapeutics, Inc, now recruiting.

## Summary

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors is a phase 2/3 interventional study registered as NCT06493552 by Vasgene Therapeutics, Inc, with 700 participants planned, started 2025-03-15 and due to reach its primary completion in 2029-09. Interventions recorded: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin and Enfortumab vedotin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06493552
- Phase: 2/3
- Setting: A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors
- Sponsor: Vasgene Therapeutics, Inc
- Enrolled: 700

## Sources

- ClinicalTrials.gov NCT06493552: https://clinicaltrials.gov/study/NCT06493552

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [VasGene Therapeutics](https://onco.cc/companies/vasgene-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06493552.json